EMA Application withdrawn: Pioglitazone Teva Generics (pioglitazone hydrochloride) — Teva Pharma B.V.

View source ↗

Summary

The EMA withdrew the application for pioglitazone hydrochloride generic by Teva Pharma B.V. (Pioglitazone Teva Generics) for Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone Teva Generics (pioglitazone hydrochloride) (pioglitazone hydrochloride)

Snippet

Status: Application withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Teva Pharma B.V.. Decision date: 23/09/2011